nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study
|
Wettergren, Yvonne |
|
2014 |
75 |
1 |
p. 37-47 |
artikel |
2 |
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function
|
Sharma, Sunil |
|
2014 |
75 |
1 |
p. 87-95 |
artikel |
3 |
Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor
|
Koo, Dong-Hoe |
|
2014 |
75 |
1 |
p. 173-182 |
artikel |
4 |
Atrial natriuretic peptide protects against cisplatin-induced acute kidney injury
|
Nojiri, Takashi |
|
2014 |
75 |
1 |
p. 123-129 |
artikel |
5 |
Biological evaluation of a novel sorafenib analogue, t-CUPM
|
Wecksler, Aaron T. |
|
2014 |
75 |
1 |
p. 161-171 |
artikel |
6 |
Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death
|
Singh, Simendra |
|
2014 |
75 |
1 |
p. 1-15 |
artikel |
7 |
Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections
|
Wright, Karen D. |
|
2014 |
75 |
1 |
p. 27-35 |
artikel |
8 |
Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer
|
Kontopodis, E. |
|
2014 |
75 |
1 |
p. 153-160 |
artikel |
9 |
Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer
|
Haroun, F. |
|
2014 |
75 |
1 |
p. 207-214 |
artikel |
10 |
EGFR–TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation
|
Koo, Dong-Hoe |
|
2014 |
75 |
1 |
p. 197-206 |
artikel |
11 |
Erratum to: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer
|
Hochster, H. S. |
|
2014 |
75 |
1 |
p. 25 |
artikel |
12 |
Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity
|
Levinsen, Mette |
|
2014 |
75 |
1 |
p. 59-66 |
artikel |
13 |
Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing
|
Inoue, Kouichi |
|
2014 |
75 |
1 |
p. 49-58 |
artikel |
14 |
Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer
|
Hochster, H. S. |
|
2014 |
75 |
1 |
p. 17-23 |
artikel |
15 |
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
|
Tolcher, Anthony W. |
|
2014 |
75 |
1 |
p. 183-189 |
artikel |
16 |
Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer
|
Uwagawa, Tadashi |
|
2014 |
75 |
1 |
p. 191-196 |
artikel |
17 |
Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews
|
Eiseman, Julie L. |
|
2014 |
75 |
1 |
p. 143-152 |
artikel |
18 |
Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration
|
McCune, Jeannine S. |
|
2014 |
75 |
1 |
p. 67-75 |
artikel |
19 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies
|
Marostica, Eleonora |
|
2014 |
75 |
1 |
p. 111-121 |
artikel |
20 |
Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies
|
Noh, Yook-Hwan |
|
2014 |
75 |
1 |
p. 97-109 |
artikel |
21 |
Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery
|
Lim, Hyun-ju |
|
2014 |
75 |
1 |
p. 77-85 |
artikel |
22 |
Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors
|
Edeline, Julien |
|
2014 |
75 |
1 |
p. 215-219 |
artikel |
23 |
TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts
|
Croucher, Jamie L. |
|
2014 |
75 |
1 |
p. 131-141 |
artikel |